health
As FDA approves new marketing for nicotine pouches, some doctors sound alarms
Updated on: August 5, 2026 / 5:49 PM EDT / CBS News
TL;DR
- The FDA has authorized marketing for four new flavored nicotine pouch products, part of a trend of approving such products after considering public health impact.
- Brands like "on!" and ZYN, manufactured by subsidiaries of Philip Morris International and Altria Group, are among those approved.
- ZYN received the first "Modified Risk Tobacco Product" designation for a nicotine pouch brand, claiming lower risk of certain diseases compared to cigarettes.
- Health advocates raise concerns about flavored nicotine pouches appealing to children and leading to nicotine addiction.
- Manufacturers state that flavors help adults transition away from cigarettes and that ZYN is intended for legal-age nicotine consumers.
- Nicotine pouches are the fastest-growing segment of the U.S. tobacco market, with significant sales increases.
- Critics fear a new generation could become addicted to nicotine, and more research is urged.
- About 460,000 middle and high school students reported using nicotine pouches last year, making them the second most common tobacco product for youth.
- Potential health risks include nicotine addiction, cardiovascular issues (elevated heart rate, blood pressure, constricted blood vessels), and oral health problems like gum recession.
- The FDA's "modified risk" authorization does not mean products are safe, but it was based on evidence that the product helps smokers quit cigarettes.
- The FDA requires postmarket surveillance and studies, and the "Modified Risk Tobacco Product" status for ZYN will expire in five years, with potential withdrawal if youth uptake increases significantly.